Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ...
The UCSF Lynch Syndrome Center is a leading Northern California clinic specializing in Lynch syndrome, a common genetic condition increasing the risk of colon cancer and other cancers. The center ...
Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Zacks Investment Research on MSN
CTMX stock rallies on strong phase I colorectal cancer study data
Shares of CytomX Therapeutics CTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line ...
Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results